/MTCR

MTCR Stock - Metacrine, Inc.

Q: What is the analyst price target for MTCR?

Analyst price target information is not currently available for MTCR.

Q: What is MTCR's market cap?

Market capitalization information is not currently available for MTCR.

Healthcare|Biotechnology|NASDAQ

$0.58-1.29%

$0.01 (-1.29%) • Jun 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.64

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MTCR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.74

52W High$0.59

52W Low$0.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018
Revenue	N/A	N/A	N/A	$1.45M
Gross Profit	N/A	N/A	N/A	$1.45M
Gross Margin	N/A	N/A	N/A	100.0%
Operating Income	$-61,079,000	$-36,690,000	$-30,004,000	$-26,729,000
Net Income	$-61,235,000	$-36,373,000	$-29,280,000	$-25,821,000
Net Margin	N/A	N/A	N/A	-1780.8%
EPS	$-1.45	$-3.87	$-1.52	$-1.35

Company Overview

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Visit Website

Earnings History & Surprises

MTCR

Beat Rate

25%

Last 8 quarters

Avg Surprise

-50.6%

EPS vs Estimate

Beats / Misses

2/6

Last 12 quarters

Latest EPS

$-0.13

Q4 2022

EPS Surprise History

Q1 21

-202.6%

$-1.15vs$-0.38

Q2 21

-9.6%

$-0.57vs$-0.52

Q3 21

-1.7%

$-0.59vs$-0.58

Q4 21

-9.5%

$-0.69vs$-0.63

Q4 21

No data

Q2 22

+17.9%

$-0.32vs$-0.39

Q3 22

+62.5%

$-0.15vs$-0.40

Q4 22

-18.2%

$-0.13vs$-0.11

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2023	Nov 13, 2023	—	—	—	—
Q3 2023	Aug 8, 2023	—	—	—	—
Q2 2023	Jun 8, 2023	$-0.09	—	—	—
Q1 2023	Mar 28, 2023	$-0.14	—	—	—
Q4 2022	Nov 14, 2022	$-0.11	$-0.13	-18.2%	✗ MISS
Q3 2022	Aug 9, 2022	$-0.40	$-0.15	+62.5%	✓ BEAT
Q2 2022	May 12, 2022	$-0.39	$-0.32	+17.9%	✓ BEAT
Q4 2021	Dec 31, 2021	—	$-0.33	—	—
Q4 2021	Nov 12, 2021	$-0.63	$-0.69	-9.5%	✗ MISS
Q3 2021	Aug 12, 2021	$-0.58	$-0.59	-1.7%	✗ MISS
Q2 2021	May 13, 2021	$-0.52	$-0.57	-9.6%	✗ MISS
Q1 2021	Mar 18, 2021	$-0.38	$-1.15	-202.6%	✗ MISS
Q4 2020	Nov 12, 2020	$-0.41	$-1.41	-243.9%	✗ MISS
Q3 2020	Sep 16, 2020	—	$-0.36	—	—
Q1 2020	Mar 31, 2020	—	$-0.42	—	—
Q4 2019	Dec 31, 2019	—	$-0.38	—	—
Q3 2019	Sep 30, 2019	—	$-0.44	—	—